£8.9M
The round was led by We Venture Capital and Cross-Border Impact Ventures to fund the global commercialisation of its liquid biopsy technology.
Oxford Cancer Analytics
Oxford Cancer Analytics develops blood tests for early cancer detection using proteomics and artificial intelligence.
£13.2MTotal raised
Oxford Cancer Analytics develops blood tests for early cancer detection using advanced proteomics and machine learning. The firm focuses on minimally invasive diagnostics to improve patient outcomes in oncology.
Categories
Founders
PL
Peter Liu
CEO
Peter serves as CEO and co-founder of Oxford Cancer Analytics. He previously directed events and served as president for the Oxford University Scientific Society.
LinkedInInvestors
- £8.9M
- £3.0M
- £1.3M
Funding history
£3.0M
The funding round was led by Eka Ventures and will support international studies and product development.
£1.3M
The oversubscribed round drew participation from Cancer Research UK, Civilisation Ventures, and various angel investors.